JP2008521906A - 自閉症の治療用の組成物及び方法 - Google Patents

自閉症の治療用の組成物及び方法 Download PDF

Info

Publication number
JP2008521906A
JP2008521906A JP2007544439A JP2007544439A JP2008521906A JP 2008521906 A JP2008521906 A JP 2008521906A JP 2007544439 A JP2007544439 A JP 2007544439A JP 2007544439 A JP2007544439 A JP 2007544439A JP 2008521906 A JP2008521906 A JP 2008521906A
Authority
JP
Japan
Prior art keywords
composition
transglucosidase
group
peptidase
amylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007544439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521906A5 (enExample
Inventor
パングボーン、ジョン、ビー
ニューマン、ラリー
ロヒット メデカー
アンソニー コリアー
マー、スティーブン
Original Assignee
カークマン グループ インコーポレイテッド
ナショナル エンザイム カンパニー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カークマン グループ インコーポレイテッド, ナショナル エンザイム カンパニー インコーポレイテッド filed Critical カークマン グループ インコーポレイテッド
Publication of JP2008521906A publication Critical patent/JP2008521906A/ja
Publication of JP2008521906A5 publication Critical patent/JP2008521906A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01024—1,4-Alpha-glucan 6-alpha-glucosyltransferase (2.4.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/107—1,4-Alpha-glucan branching enzyme (2.4.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2007544439A 2004-12-01 2005-11-30 自閉症の治療用の組成物及び方法 Pending JP2008521906A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/000,668 US20060115467A1 (en) 2004-12-01 2004-12-01 Compositions and methods for the treatment of autism
PCT/US2005/043175 WO2006060414A2 (en) 2004-12-01 2005-11-30 Compositions and methods for the treatment of autism

Publications (2)

Publication Number Publication Date
JP2008521906A true JP2008521906A (ja) 2008-06-26
JP2008521906A5 JP2008521906A5 (enExample) 2008-12-18

Family

ID=36565652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544439A Pending JP2008521906A (ja) 2004-12-01 2005-11-30 自閉症の治療用の組成物及び方法

Country Status (8)

Country Link
US (2) US20060115467A1 (enExample)
EP (1) EP1817052A4 (enExample)
JP (1) JP2008521906A (enExample)
CN (1) CN101287829A (enExample)
AU (1) AU2005311975A1 (enExample)
CA (1) CA2590384A1 (enExample)
WO (1) WO2006060414A2 (enExample)
ZA (1) ZA200704677B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503586A (ja) * 2012-01-03 2015-02-02 キュアマーク リミテッド ライアビリティ カンパニー 神経障害および精神障害の行動症状を治療する方法
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
ES2636449T3 (es) * 2007-06-18 2017-10-05 Et & Ds Company Ltd Suplemento alimenticio
DK2276848T3 (en) * 2008-04-30 2015-03-09 Danisco Us Inc Improved fermentation using molasses
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP3064217B1 (en) 2009-01-06 2018-04-18 Galenagen, LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
WO2010147714A1 (en) * 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
CA2780756A1 (en) * 2009-11-23 2011-05-26 Prothera, Inc. Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10195256B2 (en) 2015-12-14 2019-02-05 Thea Fournier Enzyme formulation for reducing salicylate and other intolerance
US9775887B2 (en) * 2015-12-14 2017-10-03 Thea Fournier Enzyme formulation for reducing salicylate intolerance
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
GB201614415D0 (en) 2016-08-24 2016-10-05 Pepsis Ltd Enzymes for the treatment of human enterometabolic dysfunction
TWI658791B (zh) * 2017-09-25 2019-05-11 愛之味股份有限公司 具有調節血脂、改善腸道菌叢及提升免疫力功能的富含寡醣乳製品及其製法
EP3927180A1 (en) * 2019-02-19 2021-12-29 DSM IP Assets B.V. Method for reducing fructan in a food product with aid of invertase (ec 3.2.1.26)
CA3241942A1 (en) * 2021-12-23 2023-06-29 Amy Frances PUZEY Prevention and treatment of diseases using phytase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
JP2015503586A (ja) * 2012-01-03 2015-02-02 キュアマーク リミテッド ライアビリティ カンパニー 神経障害および精神障害の行動症状を治療する方法
JP2021001222A (ja) * 2012-01-03 2021-01-07 キュアマーク， リミテッド ライアビリティ カンパニー 神経障害および精神障害の行動症状を治療する方法
JP2019006788A (ja) * 2012-01-03 2019-01-17 キュアマーク リミテッド ライアビリティ カンパニー 神経障害および精神障害の行動症状を治療する方法
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US12485094B2 (en) 2020-09-10 2025-12-02 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
CA2590384A1 (en) 2006-06-08
US20080112944A1 (en) 2008-05-15
US20060115467A1 (en) 2006-06-01
EP1817052A4 (en) 2008-07-02
AU2005311975A1 (en) 2006-06-08
WO2006060414A2 (en) 2006-06-08
EP1817052A2 (en) 2007-08-15
ZA200704677B (en) 2008-09-25
CN101287829A (zh) 2008-10-15
WO2006060414A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
JP2008521906A (ja) 自閉症の治療用の組成物及び方法
US6783757B2 (en) Composition and method for increasing exorphin catabolism to treat autism
US9498520B2 (en) Use of proteases for gluten intolerance
US10588948B2 (en) Methods and compositions for the treatment of symptoms of Williams Syndrome
US20040057944A1 (en) Microbial enzyme mixtures useful to treat digestive disorders
US5445957A (en) Enzyme food supplement composition containing beta-fructofuranosidase, cellulase and hemicellulase
Garvey et al. Fungal digestive enzymes promote macronutrient hydrolysis in the INFOGEST static in vitro simulation of digestion
US10159721B2 (en) Enzyme formulation for use as food supplement
Nilsson et al. Hydrolysis of lactitol, maltitol and Palatinit® by human intestinal biopsies
KR0178029B1 (ko) α-D-갈락토사이드와 결합되거나 이를 함유하는 당으로 인한 위장 장애를 감소시키기 위한 조성물 및 방법
Fukami et al. In vitro utilization characteristics of maltobionic acid and its effects on bowel movements in healthy subjects
Qamra et al. A review of digestive enzyme and probiotic supplementation for functional gastrointestinal disorders
JP2009221135A (ja) 疲労軽減剤
Sequeira et al. Lactose intolerance: genetics of lactase polymorphisms, diagnosis and novel therapy
Fara et al. In vitro digestibility of oligosaccharides synthesized by dairy propionibacteria β-galactosidase from lactose, lactulose and lactitol
US20240382569A1 (en) Fungal enzyme mixtures and uses thereof
Paliulis et al. Protease, amylase and lactase enzyme stability in Gastroval® capsules after incubation at acidic pH and elevated temperature
Dimov et al. Effect of oligosaccharides on salivary α-amylase in vitro
JP5717433B2 (ja) 胆汁酸吸着用組成物
Ekun et al. Glycine max Seed Protein Hydrolysates: Antiglycation Potentials and Inhibition of Carbohydrate-hydrolyzing Enzymes
JP2024101018A (ja) 経口用組成物
JP2016132645A (ja) 血流非依存性末梢体温回復剤、及びその製造方法
JP2012140396A (ja) コレステロール低下用組成物
Satyanarayana Digestion and absorption
Murphree II et al. Systemic Enzyme Support: An Overview

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120110